Immunic Stock Fundamentals
| IMUX Stock | USD 1.24 0.01 0.81% |
Immunic fundamentals help investors to digest information that contributes to Immunic's financial success or failures. It also enables traders to predict the movement of Immunic Stock. The fundamental analysis module provides a way to measure Immunic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunic stock.
At this time, Immunic's Research Development is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 5.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 105.5 K in 2024. Immunic | Select Account or Indicator |
Immunic Company Current Valuation Analysis
Immunic's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immunic Current Valuation | 66.17 M |
Most of Immunic's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immunic has a Current Valuation of 66.17 M. This is 99.54% lower than that of the Biotechnology sector and 98.58% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.6% higher than that of the company.
Immunic Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunic's current stock value. Our valuation model uses many indicators to compare Immunic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunic competition to find correlations between indicators driving Immunic's intrinsic value. More Info.Immunic is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At this time, Immunic's Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunic by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunic's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunic's earnings, one of the primary drivers of an investment's value.Immunic Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunic's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunic could also be used in its relative valuation, which is a method of valuing Immunic by comparing valuation metrics of similar companies.Immunic is currently under evaluation in current valuation category among related companies.
Immunic Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunic from analyzing Immunic's financial statements. These drivers represent accounts that assess Immunic's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunic's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 74.9M | 239.5M | 226.4M | 44.5M | 51.2M | 48.7M | |
| Enterprise Value | 46.1M | 112.7M | 140.1M | (60.6M) | (69.7M) | (66.2M) |
Immunic Fundamentals
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 66.17 M | ||||
| Shares Outstanding | 89.93 M | ||||
| Shares Owned By Insiders | 7.72 % | ||||
| Shares Owned By Institutions | 58.08 % | ||||
| Number Of Shares Shorted | 3.03 M | ||||
| Price To Earning | (6.65) X | ||||
| Price To Book | 4.48 X | ||||
| EBITDA | (99.11 M) | ||||
| Net Income | (93.61 M) | ||||
| Cash And Equivalents | 72.77 M | ||||
| Cash Per Share | 1.85 X | ||||
| Total Debt | 1.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 0.64 X | ||||
| Cash Flow From Operations | (70.83 M) | ||||
| Short Ratio | 5.23 X | ||||
| Earnings Per Share | (2.11) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 77 | ||||
| Beta | 1.95 | ||||
| Market Capitalization | 111.51 M | ||||
| Total Asset | 54.3 M | ||||
| Retained Earnings | (410.89 M) | ||||
| Working Capital | 27.8 M | ||||
| Current Asset | 32.33 M | ||||
| Current Liabilities | 4.73 M | ||||
| Net Asset | 54.3 M |
About Immunic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 7.7 M | 8 M | |
| Total Revenue | 0.00 | 0.00 | |
| Cost Of Revenue | 111 K | 57.7 K | |
| Stock Based Compensation To Revenue | 0.00 | 0.00 | |
| Sales General And Administrative To Revenue | 0.00 | 0.00 | |
| Research And Ddevelopement To Revenue | 0.00 | 0.00 | |
| Capex To Revenue | 0.00 | 0.00 | |
| Revenue Per Share | 0.00 | 0.00 | |
| Ebit Per Revenue | 0.00 | 0.00 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunic's short interest history, or implied volatility extrapolated from Immunic options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Immunic Piotroski F Score and Immunic Altman Z Score analysis. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.